Related Experiment Video

Updated: May 4, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.2K

Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations

Natasha Walzer1, Steven L Flamm

  • 1Northwestern Feinberg School of Medicine, 675 N St Clair Galter 15-250, Chicago, IL 60611, USA.

Expert Review of Clinical Pharmacology
|January 16, 2014
PubMed

Insights

Hepatitis C virus (HCV) treatments show varied efficacy and safety in special populations. This review examines Pegylated IFN-α (PEG-IFN-α) and ribavirin in HIV coinfection, obesity, transplant recipients, children, and African Americans.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) is a leading cause of chronic liver disease and liver transplantation in the USA.
  • Pegylated interferon-alfa (PEG-IFN-α) and ribavirin are standard treatments for chronic HCV.
  • Recent years have seen expanded antiviral therapy to special populations often excluded from initial trials.

Purpose of the Study:

  • To review the clinical efficacy and safety of PEG-IFN-α and ribavirin in specific patient groups.
  • To investigate variable treatment responses and side-effect profiles in these populations.
  • To address data on HIV-coinfected, obese, liver transplant, pediatric, and African-American patients.

Main Methods:

  • Literature review of clinical studies and trials.
  • Analysis of efficacy and safety data for PEG-IFN-α and ribavirin.
  • Focus on special populations including HIV coinfection, obesity, liver transplant recipients, children, and African Americans.

Main Results:

  • Special populations exhibit variable responses to standard HCV therapy.
  • Different side-effect profiles are observed in these groups.
  • Etiologies for varied responses are still under investigation.

Conclusions:

  • PEG-IFN-α and ribavirin efficacy and safety vary significantly across special populations.
  • Further research is needed to understand and optimize HCV treatment in these diverse groups.
  • Tailored therapeutic strategies may be necessary for improved outcomes in special populations.

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.0K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
933
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615